Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Synlogic, Inc. SYBX
$0.56
+$0.01 (1.31%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
38080748.00000000
-
week52high
1.45
-
week52low
0.45
-
Revenue
1180000
-
P/E TTM
-1
-
Beta
1.01003400
-
EPS
-1.01000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 13 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 18 мар 2022 г. |
| Oppenheimer | Outperform | Perform | 24 ноя 2021 г. |
| SVB Leerink | Outperform | Outperform | 11 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 13 окт 2021 г. |
| Oppenheimer | Outperform | Outperform | 18 окт 2022 г. |
| Chardan Capital | Buy | Buy | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hurter Patricia N. | A | 91954 | 91954 | 03 янв 2023 г. |
| Barrett Peter | A | 156130 | 156130 | 03 янв 2023 г. |
| Mathers Edward T | A | 27000 | 27000 | 09 июн 2022 г. |
| Kelly-Croswell Lisa | A | 27000 | 27000 | 09 июн 2022 г. |
| Burgess Michael F. | A | 27000 | 27000 | 09 июн 2022 г. |
| Shea Richard P | A | 27000 | 27000 | 09 июн 2022 г. |
| Heffernan Michael Thomas | A | 27000 | 27000 | 09 июн 2022 г. |
| Hurter Patricia N. | A | 27000 | 27000 | 09 июн 2022 г. |
| Barrett Peter | A | 27000 | 27000 | 09 июн 2022 г. |
| Leschly Nick | A | 27000 | 27000 | 09 июн 2022 г. |
Новостная лента
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
InvestorPlace
11 мая 2023 г. в 12:38
Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it's not particularly likely to happen.
Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 09:10
Synlogic, Inc. (SYBX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.22 per share a year ago.
3 Megatrend Stocks to Buy for 10x Potential Returns
InvestorPlace
28 апр 2023 г. в 17:12
Megatrends exist across many thematic areas of the stock market. Identifying these trends usually involves analyzing key factors such as technological breakthroughs, social change, urbanization, climate change, and global wealth shifts and capitalizing on them.
Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
29 мар 2023 г. в 09:13
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Upgraded to Buy: Here's Why
Zacks Investment Research
16 янв 2023 г. в 13:33
Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).